Maintenance of response in moderate-to-severe psoriasis after withdrawal of the interleukin (IL)-17A and IL-17F nanobody sonelokimab: is there a role for IL-17F in disease reoccurrence?
Standard
Maintenance of response in moderate-to-severe psoriasis after withdrawal of the interleukin (IL)-17A and IL-17F nanobody sonelokimab: is there a role for IL-17F in disease reoccurrence? / Reich, Kristian; Cullen, Eva; Weinberg, Mark.
In: BRIT J DERMATOL, Vol. 187, No. 4, 10.2022, p. 591-593.Research output: SCORING: Contribution to journal › Other (editorial matter etc.) › Research
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Maintenance of response in moderate-to-severe psoriasis after withdrawal of the interleukin (IL)-17A and IL-17F nanobody sonelokimab: is there a role for IL-17F in disease reoccurrence?
AU - Reich, Kristian
AU - Cullen, Eva
AU - Weinberg, Mark
PY - 2022/10
Y1 - 2022/10
KW - Antibodies, Monoclonal
KW - Humans
KW - Immunologic Tests
KW - Interleukin-17
KW - Psoriasis/drug therapy
U2 - 10.1111/bjd.21617
DO - 10.1111/bjd.21617
M3 - Other (editorial matter etc.)
C2 - 35442535
VL - 187
SP - 591
EP - 593
JO - BRIT J DERMATOL
JF - BRIT J DERMATOL
SN - 0007-0963
IS - 4
ER -